巴里西提尼布用于成人亚托邦性皮炎:现实世界的有效性,安全性和反应预测指标
Niccolò Gori1,2, Lucia Di Nardo1, Elena Ippoliti2
1Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
The Journal of dermatological treatment
|November 3, 2025
概括
巴里西替尼在现实环境中证明了中度至重度的亚托皮炎 (AD) 的长期有效性和良好的安全性. 亚托皮性并发症预测到第16周对巴里西提尼布治疗的反应更好.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 随机试验显示了巴里西提尼布在中度至重度的亚托皮性皮炎 (AD) 中的疗效.
- 对AD治疗巴里西提尼布的现实世界的证据是有限的.
- 了解长期结果和反应预测因素至关重要.
研究的目的:
- 评估巴里西提尼布在成人AD患者的长期有效性和安全性.
- 在现实世界AD管理中确定治疗反应的预测因素.
- 评估巴里西提尼布对疾病严重程度和患者报告结果的影响.
主要方法:
- 这是一项多中心,回顾性和前性研究,涉及52名成年阿尔茨海默病患者,接受巴里西提尼布治疗.
- 湿疹区域和严重性指数 (EASI),身体表面积 (BSA), numeric评分尺度 (Itch-NRS) 的评估,以及在基线和多个时间点的其他结果,直到52周.
- 在第16周对最小疾病活动 (MDA) 的预测因子的分析.
主要成果:
- 在医生和患者报告的结果中观察到显著和持续的改善.
- 亚托皮性并发症与16周达到MDA (OR: 10.9; p=0.033) 的几率增加有关.
- 头部和部的参与降低了反应的可能性 (OR:0.07;p=0.028),在28名患者中发生了32起轻度至中度的不良事件.
结论:
- 巴里西提尼布在现实实践中为中度至重度的AD提供了显著的长期有效性和有利的安全性概况.
- 亚托皮性并发症是16周之前巴里西提尼布最佳临床反应的预测指标.
- 这项研究提供了有价值的现实数据,支持巴里西提尼布在阿尔茨海默病管理中的使用.
相关概念视频
01:22Dose-Response Relationship: Potency and Efficacy
6.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.3K
01:29Therapeutic Drug Monitoring: Affecting Factors
193
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
193
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475